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Introduction
While hypothesis-neutral scientific endeavours are sometimes 
referred to in derogatory terms as “stamp collecting”, the colla-
tion of molecular part lists (e.g. genes, transcripts, proteins and 
metabolites) remains a crucially important exercise, not only for 
many aspects of basic biology, but also for application to the bio-
medical sciences and drug discovery. Paradoxically, however, 
despite technical advances in analytical experimentation that 
should be making them easier to verify and quantify, definitive (or 
“closed”) counts of even just these four entities for key species 
remain largely refractive. This is particularly so for proteins, as 
the most demonstrably biologically functional of these entity sets, 
even though they were the first to emerge historically by many 
decades1. In 2001, an analysis of the first public version of the 
draft human genome included an estimate of ∼24,500 protein-
coding genes2. The general opinion at that time was that this was 
lower than expected and would thus probably rise above 30,000. 
Notwithstanding, when the more complete first reference assem-
bly (92% euchromatic coverage at 99.99% accuracy) was released 
in May 2004, the estimate was revised slightly downwards to 
∼24,0003. In the same year a detailed review appeared support-
ing a lower bound of ∼25,0004. This latter publication alluded 
to a “yoyo” effect that persisted in subsequent reviews by falling 
to ∼20,500 in 20075, rising to 22,333 in 20106, but then dropping 
to ∼19,000 by 20147. Those accepting the latter estimate may have 
felt a touch of chagrin as the count thereby fell to ∼ 1000 below 
the model worm Caenorhabditis elegans. While we humans were 
still, reassuringly perhaps, ∼ 7000 proteins ahead of the model fly 
Drosophila melanogaster, we are still ∼20,000 behind the lowly 
Paramecium (see Table 1).
This article will compare and discuss the current numbers 
(as of 1Q 2017) from major sources. The evidence types and theory 
behind protein counting have been described in many publications 
and documentation from the individual database portals, but the 
reviews referenced above provide complementary background. 
It needs to be stated that numbers used herein refer to what can 
be termed the “canonical” human proteome. This has its origins 
in the Swiss-Prot approach to protein annotation whereby pro-
tein sequence differences arising from the same genomic locus 
either by alternative splicing or alternative initiations (or permuta-
tions of both) and/or genetic variants, are all cross referenced to a 
single, maximal length, protein entry8. Importantly, while this was 
originally introduced as the curatorial strategy of choosing the 
longest mRNA for an entry, it actually turns out to have post-
genomic data support, not only in the form that coding-loci 
express a single main protein (i.e. that most predicted alternative 
transcripts may not be translated), but also that in most cases this is 
the max-exon form (i.e. the curatorial choice actually seems to be 
the biological “default”)9.
Historical growth
The set of open reading frames (ORFs) constituting the canoni-
cal human proteome can be historically followed in Ensembl 
and Swiss-Prot (as the manually reviewed and expert annotated 
sub-set of UniProtKB). Both of these are very different pipelines, 
but are partially coupled in the sense that the latter is one of the 
inputs to the automated ORF-building algorithms of the former. 
We can assess the progress of Ensembl first, since it has been 
compiling an approximation to the human proteome based on 
genomic predictions since 200110. A 2004 review assessed histori-
cal figures from the first three years, over which the total shifted 
only marginally from 24,037 to 24,0464. While a maximum of 
29,181 was reached in January 2002, this was an artefact associ-
ated with clone orientation changes caused by a switch in the 
assembly source, and this number had dropped back to 24,179 
Table 1. Human protein coding gene counts from nine different portals, collected at the beginning of 2017. Ensembl 
numbers for the yeast, worm, fly and a protozoan are included for comparison (abbreviations are defined in the text).
Source Version/date Total URL
GeneCards v4.3.4, Jan 2017 21,819 http://www.genecards.org/ 
GeneID Feb 2017 20,671 https://www.ncbi.nlm.nih.gov/gene/statistics/ 
Swiss-Prot Release 2017_01 20,171 http://www.uniprot.org/ 
neXtprot Jan 2017 20,159 https://www.nextprot.org/about/statistics 
GENECODE v25, March 2016 19,950 http://www.gencodegenes.org/stats/current.html 
Ensembl 87.38 19,915 http://www.ensembl.org/Homo_sapiens/Info/Annotation 
Vega/Havana Feb 2017 19,768 http://vega.sanger.ac.uk/Homo_sapiens/Info/Annotation 
HGNC Feb 2017 19,033 http://www.genenames.org/cgi-bin/statistics 
CCDS 20, Aug 2016 18,891 https://www.ncbi.nlm.nih.gov/projects/CCDS/CcdsBrowse.cgi 
S. cerevisiae Dec 2011 6,692 http://www.ensembl.org/Saccharomyces_cerevisiae/Info/Annotation 
C. elegans WS250, 2012 20,362 http://www.ensembl.org/Caenorhabditis_elegans/Info/Annotation 
D. melanogaster Release 6, 2014 13,918 http://www.ensembl.org/Drosophila_melanogaster/Info/Annotation 
P. tetraurelia v87.1, 2006 39,642 http://protists.ensembl.org/Paramecium_tetraurelia/Info/Annotation/#assembly 
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by the next release. Despite some year gaps (not covered by the 
current archived data sets) the older figures can be plotted with 
the most recent ones to give a 15 year-span (Figure 1).
It is important to note that, for technical reasons, the longitudinal 
Ensembl protein numbers are not strictly comparable, since the 
pipeline model, its parameterisations and data feeds, have, as one 
might expect, evolved considerably over the years (e.g. the assem-
bly source change mentioned above). This has included incremental 
improvements of various kinds (e.g. in the quality of the reference 
genome), but some changes have altered the exact definitions of 
the headline protein numbers. For example, the pseudogene figures 
given in the early 2001–3 releases needed to be subtracted from the 
totals. Those earlier numbers also specified a proportion of novel 
genes (defined as not having an exact match to RefSeq or UniProt 
entries at build time), but these tailed off from a maximum of 12,398 
in November 2001 to only 46 by 2009 (release 54).
The most recent releases have other changes that complicate 
protein counts. One of these is the inclusion of “alternative 
sequence”, referring to genomic sections that differ from the 
primary contiguous assembly. The current release of Ensembl 
(87.38) specifies 2,541 proteins in this category, but it is not clear 
which of these are just variants of those derived from the primary 
assembly. Another, somewhat enigmatic aspect, is the appearance 
in the protein count of so called “read-through” genes. These are 
defined as transcripts connecting two independent loci on the same 
strand. These debuted at 463 in release 74, via manual annota-
tion, climbing slowly to the current total of 526. While they are 
also included in the NCBI genome annotation, these have not 
been included in the Figure 1 counts because, if they exist at all as 
translated chimeric proteins, they are non-canonical by definition. 
Despite these shifts in exactly what the protein numbers represent, 
we can draw three principle conclusions from Figure 1. These are: 
a) yo-yoing has at least subsided, if not ceased; b) the number has 
plateaued at just below 20,000; and c) the pipeline has ceased to 
spawn significant numbers of novel proteins (i.e. they are now pre-
dominantly “seen before”).
One of the core operations for Ensembl is resolving transcripts 
and their mRNA coding sections (CDSs) against ORFs pre-
dicted ab initio. Swiss-Prot, on the other hand, has historically 
been doing this for mRNA-to-protein independently of genomic 
coordinates (although it increasingly now maps the two together 
where possible). Over the years, the criteria and manual triage for 
defining canonical ORFs have been consistently applied in 
Swiss-Prot. This means the growth rate can be straightforwardly 
recorded by slicing Swiss-Prot human proteins by “create date” 
(Figure 2). The pattern is interpretable as a concerted effort 
towards provisional closure of the proteome at 19,658 by 2008. 
Subsequent increases were essentially incremental, climbing 
slowly to 20,168 by 2017.
While issues around evidence types will be addressed later, a 
simple filter can be applied to count just those proteins with either 
transcript and/or other forms of experimental support for their 
existence. The result, in the Figure 2 plot, shows this difference 
to be fairly constant (i.e. that in the order of ∼1,400 sequences 
remaining experimentally unsupported). There are three other 
salient features. The first is that the total has only increased by a 
modest 516 since 2009, whereas Ensembl shrunk by 1,455 over 
the same period. They have thus both converged towards ∼20,000 
(it is not clear if the two sets are congruent for the same ORFs, but 
this question will be addressed later). However, there were already 
Figure 1. Protein counts from the Ensembl pipeline database releases over the first three years and last seven years. The latter are only 
those from the current archive that have protein rebuilds rather than maintenance/patch releases with nearly identical numbers.
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indications of approximate concordance as early as 2001, where 
adding the Ensembl novels to the Swiss-Prot knowns reached 
18,191. The inference is that the number of novel proteins confirmed 
since 2001 is less than 2000. Note also that many are TrEMBL-to-
Swiss-Prot promotions (i.e. with data already surfaced) rather than 
de-novo deposited protein sequences. By comparing 2009 with the 
subsequent seven years we can also infer that Swiss-Prot has not 
purged significant numbers of accessions (i.e. they have revised 
sequences but generally not removed them).
Current counts
We can move on from tracking historical numbers to taking a con-
temporary snapshot of major sources (including the two already 
described) that are well established and regularly declare revised 
protein counts (Table 1). There are many aspects that could be 
expanded on from this set, but the feature that immediately stands 
out is the difference of nearly 3000 between highest and lowest 
(i.e. 13%). The highest figure comes from what can be considered 
a meta-source, GeneCards, that merges different pipeline outputs, 
so this could be expected to be an upper bound11. The protein- 
coding set from the NCBI genome annotation pipeline ranks 
second but there are some caveats regarding comparability 
with the other sources12. One of these is the inclusion of 1235 
“LOC” entries with low homology support. Although 107 of these 
do have Ensembl gene IDs, none have been assigned Human 
Gene Nomenclature Committee (HGNC) symbols. Removing 
LOCs from the NCBI protein set would drop them down to seventh 
at 19,436.
The next two sources are related in that neXtprot takes the human 
Swiss-Prot set as a starting point for evidence expansion and 
interrogation enhancements. This is why these have (almost) the 
same count (the residual differences being due to synchronisation 
timings)13. The next three sources are also coupled in the sense 
that not only are GENECODE and Vega marked-up in Ensembl, 
but there are plans to merge the three. However, they do show a 
small difference of 182, with the lowest being the Vega pipe-
line (as Havanna manual curation). But even from Vega, there is 
a substantial drop of 735 to the stringently reviewed approved 
protein-coding gene-based assignments from the HGNC. The 
lowest number in Table 1, coming in at just below 19,000, comes 
from the Consensus Coding Sequence (CCDS) project. These cor-
respond to a core set of proteins annotated as having full length 
transcripts that exactly match reference genome coordinates.
Some sources have invested effort into mapping between each 
other’s identifiers. This can establish if the protein sequence in 
pipeline output A is the same as pipeline B. However, the fidel-
ity of such a mapping (and consequent cross-reference reciproc-
ity) depends on differences in methods and stringencies. For 
example, for all intents and purposes the beta-secretase 1 entry 
(BACE1) is the same across all 9 pipelines. However, a different 
population variant was chosen on each side of the Atlantic. There-
fore, the RefSeq and Gene ID sequence NP_036236 differs by 
one residue (481 Cys → Arg) from the Swiss-Prot and Ensembl 
sequence as P56817. Note also that HNGC does not instanti-
ate sequence entries in the way that the other pipelines do, but 
Figure 2. Protein counts from human UniProtKB/Swiss-Prot by create date (red). The blue columns include the additional selection 
for existence evidence at the protein or transcript levels (note the date is just for the entry into Swiss-Prot, not the first appearance of the 
sequence in TrEMBL that can be many years earlier).
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collates cross-references, so in this case HGNC 933/BACE1 points 
to both sequences. The process of cross-referencing between 
multiple annotation sources allows the generation of both inter-
sects and differences. Crucially, in terms of protein counting, this 
gives us the possibility to discern where they are concordant or 
discordant and (on a good day) we may be able to identify causes 
for the latter.
Cross-reference counting
All nine sources in Table 1 provide some extent of cross- 
referencing between what should be the same protein in different 
sources (also referred to as cross-mapping). However, the choice 
was made here to exemplify just four identifiers, Swiss-Prot 
accession numbers, HGNC IDs (directly, or via the current gene 
symbols) Ensembl gene IDs and NCBI Entrez Gene IDs. These 
were chosen for their global prominence but also methodologi-
cal complementarity. This derives from the fact that that the first 
two are essentially automated pipelines (but different), while the 
second two are primarily manual expert annotation operations (but 
also different). Each of the four offers their own internal ways of 
querying cross-references, including BioMart installations14 or 
downloadable mapping tables for this to be done extrinsically. 
However, because it has the largest number of selectable cross- 
references, as well as extended options for live-linked result 
displays and filtered downloading, the UniProt interface was 
used here. Intersects for the four sources can be seen in Figure 3.
Figure 3 can be explained as follows: The queries executed gave 
the totals indicated in the segments. Note that some segments are 
empty, because, by definition, the identifier mapping has been done 
“inside” Swiss-Prot (even if in some cases the external sources 
collaborated in generating the mappings). By comparing with 
Table 1, we can thus see that 2,923 NCBI proteins did not map at 
all (which includes most of the LOCs). Similarly, 834 Ensemble 
protein gene IDs also did not map. For HGNC, on the other hand, 
we see the cross-reference result is actually 905 higher than the 
distinct identifier count at source. One explanation could be a pro-
portion of a one-to-many relationship (e.g. Swiss-Prots with more 
than one HGNC). Some were identified, such as haemoglobin 
subunit alpha (P69905) that maps to HGNC HBA1 and HBA2.
A notable result from Figure 3 is that a 1:1:1:1 mapping (i.e. four-
way concordance) is achieved for only 18,690 proteins, lower than 
any of the totals from Table 1. Detailed analysis of all the segments 
cannot be presented here but some trends can be noted. Starting 
with the 187 in the “SP” segment (i.e. Swiss-Prot only, absent 
from the other three), the majority of the protein names are given 
as “putative” or “uncharacterised”. The 391 common elements in 
“SP”, “EN” and “HG” (i.e. missing in NCBI Gene) are clearly 
dominated by variable domains of immunoglobulin light chains 
and HLA class I histocompatibility antigen alpha chains, the poly -
morphic nature of which necessitates a level of manual annotation 
that may not have been compatible with the NCBI pipeline automa-
tion. The 179 common elements in “SP”, “HG” and “GI” (i.e. miss-
ing in Ensembl) are enriched for “Uncharacterized protein” from 
the so called Chromosome ORF predictions. The large set of 697 
common elements in “SP” and “HG” (i.e. missing in NCBI Gene 
and Ensembl) are heterogeneous but show enrichment for trans-
lated endogenous retrovirus transcripts, putative uncharacterized 
proteins encoded by LINC loci and include 41 odour receptors. 
Notably, in these three sets, the HGNC cross-references classify 
them as not being within their own protein-coding set of 19,033, 
but rather as endogenous retrovirus, long non-coding RNAs and 
pseudogenes, respectively. This particular discordance (i.e. in 
UniProt but not a protein according to the HGNC) explains the 
1: many cross-references mentioned at the start of this section. A 
duplicate check on the 960 indicated only 152 could be ascribed to 
Swiss-Prots with multiple HGNCs. It can also be seen in Figure 3 
that two of the Swiss-Prot intersects are empty. The explanation 
is that Ensemble and NCBI Gene have consolidated mapping 
reciprocity for proteins in Swiss-Prot (but, as mentioned above, 
many proteins from these two sources are still nominally “outside” 
Swiss-Prot).
As one of its powerful utilities, we can interrogate ∼ 90 cross 
references in UniProt. While not all of these are human-relevant 
we can chose those to compare with Table 1. This has already 
been done for the four above but can be extended. For example, 
we can determine counts of 18,384 from CCDS and 19,940 for 
GeneCards. Note both of these are below the in situ counts by 510 
and 1,871 respectively (GENCODE and Vega do not currently have 
cross-references inside Swiss-Prot). In some cases it may be possi-
ble to investigate counts reciprocally. For example, from the HGNC 
protein-coding download table we can establish that the 19,035 
rows in the UniProt mapping column contained 18,997 Swiss-
Prot IDs. The same table includes 19,035 Vega Gene ID mappings 
that also collapse to 18,973 distinct entries. This confirms what 
was implicated already above, as a small proportion of multiple 
Swiss-Prots < > HGNCs is also occurring for HGNC < > Vega. 
Cross-mapping counts can similarly be explored via other 
sources for comparison, depending on what query and/or down-
load options are available. However, accumulating such results can 
Figure 3. Intersects between identifier cross-references 
recorded from the UniProt interface. The results are generated 
via cross-reference totals according to UniProt, not from the sources 
in situ. EN, Ensembl; SP, Swiss-Prot; HG, Human Gene Nomenclature 
Committee; GI, NCBI Entrez Gene.
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quickly generate large Venn-type sets that generally end up being 
more confusing than illuminating.
Following on from above, since they are derived from structure 
data sources, cross-references give precise protein counts; but they 
also have associated equivocality (even though they will be used 
further in this report). For this reason, it is important to understand 
(e.g. via source documentation) technical differences in exactly 
how the mappings are determined. A second problem is they may 
be circular (i.e. source B may collegially accept A< > B map-
pings from source A without independently verifying the reci-
procity of B >A). The third problem is synchronisation, where 
release dates are at different intervals (and may not always include 
mapping refreshes). The forth problem is the “churn” rate (appear-
ance and/or disappearance of protein records) in genome resources. 
This is much lower that is was some years ago, but can still be an 
issue.
Existence evidence
In the context of advancing towards proteomic “closure”, the 
imperative to verify the existence of an in silico database ORF as an 
in vivo protein translation product is obvious. By definition, the pre-
requisite mRNA transcription also needs experimental verification; 
especially if the ORF is only a genomic DNA prediction. However, 
on its own, active transcription is insufficient to prove translation, 
even with a predicted CDS, and it is established that pseudogenes 
can exhibit low-level transcription15. While it has inherited the cat-
egorisations from UniProt, the neXtprot database has a particular 
focus on the evidence code system and has set up collaborations to 
extend experimental support in general13. The outlines of this can 
be seen in Figure 4.
The categories (expanded on in the neXprot documentation) are as 
follows:
1.    PE1: evidence that includes at least partial Edman sequenc-
ing, mass spectrometry (MS) with a threshold of 2 peptides 
of at least 9 amino-acids, X-ray or NMR structure, protein-
protein interaction data or detection by antibodies (Abs).
2.    PE2: not proven at protein level but has transcription data 
(e.g. cDNA, RT-PCR or Northern blots).
3.    PE3: probable existence based on orthologues with high 
similarity scores being found in related species.
4.    PE4: no evidence at the protein, transcript, or homology 
levels.
5.    PE5: may be a spurious in silico translation of a non-coding 
transcript.
There is now a community effort to promote more proteins to 
P1 using both MS and Abs, so we can go into these in more 
detail. The former has a long history with a proprietary project 
reporting MS identification of 14,223 human proteins as early as 
200416. An analogous public effort described the verification of 
11,115 Ensembl coding sequences, made available in the first data 
release of the ProteinAtlas (PA) in 200517. By 2017 the Human 
Proteome Organisation has been extensively engaged in MS 
initiatives, particularly in regarded to the “missing proteins” 
(i.e. those still in P2 to P5) that remain refractory to tryptic peptide 
verification at the necessary stringency. This aspect has been the 
subject of several recent reviews and so does not need expanding 
here18,19.
As another important methodological push, antibody-based pro-
teomics has developed more recently into a large-scale enterprise. 
This was first described in 2014 as the Human Protein Atlas project 
with its own associated database20. This has now been extended 
with the setting up of an International Working Group for Antibody 
Validation and the accompanying Antibodypedia database21. These 
have the objective to increase the reproducibility of protein iden-
tification and ultimately, as with the MS initiatives, to move more 
sequences up to the P1 evidence code)
Figure 4. Protein existence codes and their occupancy statistics from neXtprot.
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We can use the categories above to further “slice and dice” cross-
referencing to gain more insight into particular subsets (e.g. via 
downloadable identifier sets for P1to P5). The possible query com-
binations are many, so we need to frame useful questions. Notably, 
it is now possible to select proteins supported by PA MS support 
entries (17,084) or HPA (16,800) or both (15,189) (n.b. numbers 
differ slightly from those in neXtprot of 18,083 for PA and 16,473 
for HPA). In terms of questions, an example that can be posed is 
“how many proteins, either supported by HPA or PA, overlap with 
the 4-database consensus set generated in Figure 3?” The result 
(Figure 5) effectively intersects the in silico with the in vivo evi-
dence sets.
As was done for Figure 3, lists from the Venn sections were input 
to the UniProt ID mapping interface to examine trends. Not all of 
these can be discussed here, but looking at the unique sets exposed 
some initially counter-intuitive results. For example, the 4-way only 
(734) included 214 P1s, but without HPA or PA cross-references. 
This is because P1 also includes 3D structures and interaction 
data. Looking at the 152 HPA-only set included 101 at P4 or P5 
levels (i.e. unexpectedly high for the implied Ab confirmation 
which might be expected to push them up to P1). It turns out 
there is a cross-reference specificity problem from the inclusion 
of uncertain results. The HPA link (for the 16,800) actually means 
the protein has been tested (i.e. had an antibody raised against 
peptide sections) but is not necessarily confirmed. The histochem-
istry support status, including consistency with two sources of 
transcript data are commented on in each HPA entry. However, 
from the HPA download for 16.1, only 10,230 (of the Ensembl 
proteins as primary identifier) are designated as “approved” or 
“supported” at the histochemistry level. Examples of evidence 
complications include the 40-residue of putative protein 
FAM86JP as the Swiss-Prot entry Q05BU3. Flagged as P5, 
this shows anomalies including designation as a pseudogene by 
HGNC (n.b. it has neither GeneID nor an Ensembl cross-reference 
which excluded it from the 4-way set) and the HPA entry 
ENSG00000186523-FAM86B1 was flagged as uncertain based on 
two antibodies. A second example exposes a different problem. The 
putative uncharacterized protein C7orf76 (Q6ZVN7) is mapped 
from UniProt to a different protein in HPA as ENSG00000127922-
SHFM1 (i.e. P60896). The miss-mapping appears to be extrinsic 
to HPA and in this case could be a UniProt < > Ensembl problem 
(which is why this is not in the 4-way set). It is important to empha-
sise that none of this is about fault finding, but these examples attest 
to the technical challenges of evidence classifications and mapping 
fidelity.
Inspecting the 360 “PepAt” (i.e. PeptideAtlas only) set reveals a 
different set of interpretive challenges. An example is the small-
est of the set at only 11 residues as morphogenetic neuropeptide 
(P69208). This has no genomic annotation, but does have an appar-
ent match in PeptideAtlas for the peptide QPPGGSKVILF. The 
Swiss-Prot entry has its origins in an Edman sequencing result from 
1986 and is consequently indicated as “Experimental evidence at 
protein level”, but has been dropped from neXtprot. A large pro-
portion of the rest of the 360 are immunoglobulin heavy variable 
and HLA class I histocompatibility antigen chains for which the 
ability of the PeptideAtlas system to resolve into separate proteins 
is unclear.
Small proteins
Back in 2004, it was already mooted that a significant expansion in 
protein number was likely to occur via the discovery of small ORFs 
(smORFs). However, this was not supported by Swiss-Prot statis-
tics at that time4. In the intervening decade, the smORF question 
has surfaced regularly22 and it now overlaps with the two closely 
related themes of de novo protein evolution (i.e. recent non-coding 
to coding transitions)23 and ribosomal profiling experiments 
attempting to define the translation of novel smORFs from what 
was hitherto classified as non-coding RNA24. In addition, the 
theme of existence evidence discussed above is also relevant, since 
whatever data support type is being sought (e.g. active transcrip-
tion plus detection by MS or Abs), the experimental verification 
of smORFs becomes more difficult.
An obvious approach to this topic is to repeat the exercise first 
performed in 20044, namely splitting the smORF count in Swiss-
Prot by create date. By setting a cut-off of 100 residues, the 
current total is 682/20,168. This can be compared with the cor-
responding 2009 totals of 612/19,675. This establishes that the 
proportional smORF content has only risen from 3.1% to 3.3%. 
In addition, from the latest 2017 size cut, 161 of the 682 do not 
have an HGNC biotype designation as protein-coding. Many also 
only have the protein existence support as Edman sequencing reads 
from the earliest Swiss-Prot releases. These short sequences are 
difficult to genome map and/or re-confirm by MS, which is why 
six were recently purged from neXtprot (P.Gaudet personal com-
munication). We are thus presented with a paradox that, despite 
many reports of putative novel human smORF discovery, very few 
are crossing the Swiss-Prot evidence threshold for becoming new 
protein entries.
Figure 5. Swiss-Prot cross-reference intersects between the 
4-way confirmed set from Figure 3, the Human Protein Atlas 
(HPA), and the Peptide Atlas.
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Notwithstanding, recently confirmed smORF examples have sur-
faced that are informative from the protein counting viewpoint. The 
first of these, the apelin receptor early endogenous ligand, was inte-
grated into Swiss-Prot in 2014 (HGNC symbol APLEA, synonyms 
Elabela, Toddler; see Swiss-Prot P0DMC3 for cross-references 
including links to the discovery papers). It was in fact “hiding in 
plain sight” in so far as its full-length cDNA (AK092578) had been 
in GenBank since 2008. However, since this sequence translates 
into eight possible smORFs, the submission process for the high-
throughput cloning project (sensibly) chose not to annotate a CDS 
in the feature lines of this prostate library entry, since there was no 
basis on which to choose any of the possible translations by protein 
similarity at that time (although arguably, manual sequence analy-
sis, including TBLASTX, might have given clues). Significantly 
though, this transcript had originally been annotated in Vega as a 
Long non-coding RNA (LncRNA) giving rise to speculation that 
additional cryptic smORFs could be “hiding” in other LncRNAs. 
Such a second case has in fact been described in 2016 in paper enti-
tled “A peptide encoded by a transcript annotated as long noncod-
ing RNA enhances SERCA activity in muscle”, although the work 
was done in mouse25. The publication was processed by Swiss-Prot 
in March 2016 to generate P0DN83 and P0DN84 for a 34 residue 
mouse and human proteins, respectively.
These two smORFs illustrate a spectrum of evidence differences 
as follows:
•  In terms of transcript support, APLEA has been re-cloned 
as KJ158076 with a submitted CDS, but this is not yet 
incorporated in the Swiss-Prot annotation. The DWORF 
authors mention obtaining cDNAs but have neither 
deposited human or mouse mRNA accession numbers. 
There are many TBLASTN matches as supporting evi-
dence for the protein (not withstanding miss-matches, 
see below) both to mammalian sequences designated as 
LOC non-coding RNAs and over 30 human expressed 
sequence tag (EST) mRNAs.
•  APLEA has three-way genomic support and a CCDS, while 
DWORF has no human genome cross reference in Swiss-
Prot. The mouse paralogue does have an Ensembl protein 
mapping (ENSMUSG00000103476) despite still being 
flagged as an LncRNA gene in the Mouse Genome Atlas. 
However, multiple lines of evidence (Southan, unpub-
lished observations) indicate the correct human sequence 
is the 35 resides represented in ENSG00000240045 (via 
Vega) as TrEMBL A0A1B0GTW0 (but circularly as 
this was picked up from Ensembl) and independently as 
ACT64388 from 2009. The predicted transcript is classi-
fied by NCBI as a non-coding LOC100507537.
•  Neither APLEA nor DWORF have any cross-references 
in the seven MS sources in UniProt. Note that APLEA 
cannot pass the double 9-mer criteria for neXtprot, and 
DWORF only has a single predicted tryptic peptide. 
Whether either protein passes the verification threshold 
for MS datasets in the future remains to be seen.
•  Publications for both APELA and DWORF have included 
Western blots from Abs raised against peptides (but 
mouse for the latter). However, neither yet has an HPA 
entry. While the possibility of inclusion in a future update 
is clear for APELA, there may not only be technical chal-
lenges from the small size of DWORF, but also, since 
HPA uses Ensembl IDs for its primary identifiers, this 
protein and its transcript would need first to be resolved 
in a future Ensembl release (n.b. LOC100507537 appears 
to have somehow parsed HPA transcript data, but this 
may be a miss-mapping).
•  Replication of the basic findings and expanded aspects 
of in vivo function have been consolidated in numerous 
publications for APELA, including a 2017 paper26. While 
the experimental characterisation of DWORF rests on 
one study done with mouse so far25, consolidation of the 
human protein evidence is to be expected in forthcoming 
work.
To summarise the implications; the discovery of additional 
smORFs seems certain, especially given that the putative LncRNA 
gene count has recently risen to 27,91927. However, the question 
remains as to how many will be verified to the evidence level 
sufficient to enter the major genome and protein portals (even 
though it will be challenging to obtain Abs and MS verification 
data). On a continuum of what we might expect between 10, 100 or 
1000, the middle estimate seems most likely.
Pharmacological interaction intersects
This last section assesses the corroboration of data linkages by 
existence evidence and other types of concordance. Many of the 
Swiss-Prot cross-references are related to protein function and other 
attributes such as tissue distribution or post-translational modifica-
tion. Others would include pathway membership, protein-protein 
interactions, Genome Ontology categorisation, disease associa-
tions, interactions between enzymes and substrates, drugs and their 
targets, as well as endogenous ligands for receptor proteins. The 
advantage of the analyses described above is that results centred 
on functional categories can be intersected with independent cross-
references. This can be exemplified by selecting the curated ligand 
interactions in the IUPHAR/BPS Guide to PHARMACOLOGY28 
(GtoPdb) that are included in the set of five chemistry (interaction) 
cross-references. The current UniProt has 1,460 human Swiss-
Prot records (as defined by the GtoPdb criteria for submitting the 
links) that have publication-supported molecular interactions. The 
majority are pharmacologically active small-molecules, but the 
curated relationships include some protein-protein interactions, for 
example, antibody ligands directed against cytokine targets (n.b. a 
proportion of these proteins are derived from a new project as the 
Guide to Immunopharmacology). The result of the corroboration 
analysis is shown in Figure 6.
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We can see the results of a three way comparison in Figure 6 
between existence evidence, four-source convergence and GtoPdb 
entries. The first feature to note is that not all proteins with 
existence evidence are in the four-source set, and vice versa. 
Possible systematic reasons behind this cannot be explored here, 
but may be related to the points discussed for Figure 5. The key 
observation for GtoPdb is that, reassuringly, 1,450 entries inter-
sect with both existence evidence and four-source identifiers. 
Notwithstanding, there are nine intersects with the existence set 
but not four-source corroborated with one vice versa (i.e. in the 
four-source set but not evidence-supported). Given that GtoPdb 
interactions are expert-curated, the result from Figure 6 raises 
questions about the annotation of the 10 protein entries. These 
were followed up to establish that the lack of evidence support for 
P0C264 arises from the absence of an mRNA entry (i.e. it remains 
a genomic prediction). The existence of this kinase seems well 
supported (e.g. via CCDS74457), but a cloned cDNA would be 
an important consolidation. Inspection of the other nine sequences 
also supported their existence but they all had a mixture of cross- 
referencing failures that had excluded them from the four-source 
set. For example, for the aspartyl aminopeptidase, DNPEP 
(Q9ULA0) the protein is solidly supported even to the extent of 
a PDB structure, but the Entrez GeneID is missing (although this 
is cross-referenced by HGNC). Likewise, the alpha-2B adrenergic 
receptor, ADRA2B (P18089) is solidly supported, but in this was 
missing the Ensembl cross-reference (it turns out from Swiss-Prot 
update enquiry this was due to an unusual accession number change 
associated with a TrEMBL to Swiss-Prot transition, Gasteiger, 
personal communication). In both cases GtoPdb had in fact been 
manually curated in the correct links for the Entrez Gene ID in 
Target ID 1559 and Ensembl Gene for Target ID 26, respectively 
(n.b. the appropriate UniProt corrections have been suggested 
via the feedback form). This cross-checking for GtoPdb targets 
thus proved a useful exercise that will be re-visited as our protein 
content expands.
Conclusions
Despite over 16 years having elapsed since the first draft human 
genome, the diversity of current counts indicates that progress 
towards what the community might consider a gold-standard 
set of canonical protein sequences, remains frustratingly slow. 
This is especially so considering that the “zone of equivocality” 
lies only between an upper bound of ∼ 20,000 and a lower one of 
∼18,500. The slow progress towards closure is clearly a reflection 
of both the inherent biological complexity of protein translation, 
as well as the challenges of combining automated annotation 
with various proportions of expert curation needed to define the 
entire expressed genomic landscape29. There are of course cave-
ats, even with the concept of closure, in so far as recent evidence 
indicates that each of us, on average have at least 100 protein 
loss-of function variants (i.e. proteomes are “personal”)30.
The wider bioscience community could be forgiven being 
puzzled that major global efforts continue to produce different 
sets of canonical proteins at roughly the same time from the same 
primary data (leaving aside another layer of yet more inter-source 
differences in alternative splice and/or initiation forms). Those 
of us with some insight into the bioinformatic, genomic and pro-
teomic challenges might be more sanguine in our judgment, but 
the criticism still stands (note also that human is the testbed from 
which the community needs progress to analogous proteomic 
closure for at least mouse, rat and Zebrafish). Approaching the 
question as to why this situation persists and possible solutions, 
would necessitate a detailed comparison of the underlying assump-
tions, data processing models and pipeline parameterisations. 
However, inter-source clustering of explicit protein sequences 
could make identifying difference more effectively than cross- 
references alone (e.g. a possible resurrection of the Human Protein 
Index initiative31).
Regardless of the technical options to solving the problem, 
substantial resources have been committed over decades by the 
major gene and protein annotation resources globally. We should 
thus expect more inter-team collaboration dedicated to harmonis-
ing amongst themselves for the mere ∼2000 protein sequences 
in question (i.e. not many compared to the 0.55 million and 
77 million processed in Swiss-Prot and TrEMBL respectively). It 
could be argued that additional (collective) manual curation would 
Figure 6. Corroboration of human proteins in Swiss-Prot with 
ligand interactions in GtoPdb (selected as “Guideto- 
PHARMACOLOGY” in the Chemistry cross-references). The first 
of the two intersected lists are labelled as “Prot Exist” with evidence 
at the transcript and protein levels (i.e. PE1 and PE2 from Figure 4), 
and the 4-way major source consensus set (i.e. the central panel of 
Figure 3).
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be needed to accomplish this, but the consequent improvement 
in silico concordance could then be consolidated by an expansion 
of experimental existence verification both in vitro and in vivo. 
This could include a supply of expressed protein standards, 
advances in MS-based proteomics, including sets of synthetic 
proteotypic peptides for spiking experiments32, deep transcript 
profiling by RNA-seq and the increased availability of validated 
antibody reagents.
Data availability
These statistics on protein numbers are presented and compared 
here in good faith and with implicit expectation that they should 
be reproducible, including by others who may want to repeat 
and/or extend these types of analyses. Notwithstanding, this may 
be confounded by several factors that could give rise to slightly 
different results (but it is hoped not major discrepancies). The most 
obvious is data updates that can be as frequently as monthly for 
some sources (e.g. since the completion of this work UniProt 
notched up to UniProt release 2017_03 on March 15, 2017 with 
the human SwissProt count increasing, from Table 1, by 13 pro-
teins to 20,184). Another is the exact form of the queries, which 
vary between resources, particularly when each selection interface 
has a different look and feel, different syntactic formats of execu-
tion and download lists having different formats of cross-referenced 
identifier columns. One example is the need to covert UniProt 
interface queries into the equivalent SPARQL queries in 
neXtprot as shown below. The UniProt syntax to count HGNC 
cross-references, as entered in the web query box, is below:
database:(type:hgnc) AND reviewed:yes AND organism:”Homo 
sapiens (Human) [9606]”
The answer was 19967 (March 2017), but note we need to 
make to pre-selects for a) species/organism and b) “reviewed” 
to select Swiss-Prot over TrEMBL. For the neXtProt equivalent 
cross-reference query, these two pre-selects are not necessary since 
is human Swiss-Prot derived anyway. The HGNC select has the 
form below:
select distinct ?entry where {
 ?entry :reference ?ref .
 ?ref :provenance db:HGNC ;
  :accession ?ac.
 filter (regex(?ac,’^HGNC’))
}
In this case the result was 19956. The basic listings from sources 
used and some of the result sets have been made available as a 
Figshare data collection (https://figshare.com/collections/Sup-
plementary_data_for_assessing_the_human_canonical_protein_
count/371641333). If any reproducibility issues do arise, interested 
parties are welcome to contact the author. 
Competing interests
No competing interests were disclosed.
Grant information
The author was supported for part of this work by the Wellcome 
Trust (grant number, 108420/Z/15/Z). 
The funders had no role in study design, data collection and analysis, 
decision to publish, or preparation of the manuscript.
Acknowledgements
The efforts of all the genomic and protein annotation teams 
referred to in this work are much appreciated. Discussions of 
discordances and other quirks should not be misinterpreted as 
criticism of the resources concerned. Thanks are due to those who 
answered questions on this topic on BioStars, various database 
helpdesks and Twitter, as well as Dr Pascale Gaudet for help with 
neXtprot queries.
References
1. Sanger F: The arrangement of amino acids in proteins. Adv Protein Chem. 1952; 
7: 1–67.  
PubMed Abstract | Publisher Full Text 
2. Lander ES, Linton LM, Birren B, et al.: Initial sequencing and analysis of the 
human genome. Nature. 2001; 409(6822): 860–921.  
PubMed Abstract | Publisher Full Text 
3. International Human Genome Sequencing Consortium: Finishing the euchromatic 
sequence of the human genome. Nature. 2004; 431(7011): 931–945.  
PubMed Abstract | Publisher Full Text 
4. Southan C: Has the yo-yo stopped? An assessment of human protein-coding 
gene number. Proteomics. 2004; 4(6): 1712–1726.  
PubMed Abstract | Publisher Full Text 
5. Clamp M, Fry B, Kamal M, et al.: Distinguishing protein-coding and noncoding 
genes in the human genome. Proc Natl Acad Sci U S A. 2007; 104(49): 
19428–19433. 
PubMed Abstract | Publisher Full Text | Free Full Text 
6. Pertea M, Salzberg SL: Between a chicken and a grape: estimating the number 
of human genes. Genome Biol. 2010; 11(5): 206.  
PubMed Abstract | Publisher Full Text | Free Full Text 
7. Ezkurdia I, Juan D, Rodriguez JM, et al.: Multiple evidence strands suggest that 
there may be as few as 19,000 human protein-coding genes. Hum Mol Genet. 
2014; 23(22): 5866–5878.  
PubMed Abstract | Publisher Full Text | Free Full Text 
8. The UniProt Consortium: UniProt: the universal protein knowledgebase. Nucleic 
Acids Res. 2017; 45(D1): D158–D169.  
PubMed Abstract | Publisher Full Text | Free Full Text 
9. Tress ML, Abascal F, Valencia A: Alternative Splicing May Not Be the Key to 
Proteome Complexity. Trends Biochem Sci. 2017; 42(2): 98–110.  
PubMed Abstract | Publisher Full Text 
10. Aken BL, Achuthan P, Akanni W, et al.: Ensembl 2017. Nucleic Acids Res. 2017; 
45(D1): D635–D642.  
PubMed Abstract | Publisher Full Text | Free Full Text 
11. Fishilevich S, Zimmerman S, Kohn A, et al.: Genic insights from integrated 
human proteomics in GeneCards. Database (Oxford). 2016; 2016: pii: baw030. 
PubMed Abstract | Publisher Full Text | Free Full Text 
12. NCBI Resource Coordinators: Database Resources of the National Center for 
Biotechnology Information. Nucleic Acids Res. 2017; 45(D1): D12–D17.  
PubMed Abstract | Publisher Full Text | Free Full Text 
Page 11 of 22
F1000Research 2017, 6:448 Last updated: 18 MAY 2017
13. Gaudet P, Michel PA, Zahn-Zabal M, et al.: The neXtProt knowledgebase on 
human proteins: 2017 update. Nucleic Acids Res. 2017; 45(D1):  
D177–D182.  
PubMed Abstract | Publisher Full Text | Free Full Text 
14. Smedley D, Haider S, Durinck S, et al.: The BioMart community portal: an 
innovative alternative to large, centralized data repositories. Nucleic Acids Res. 
2015; 43(W1): W589–W598.  
PubMed Abstract | Publisher Full Text | Free Full Text 
15. Guo X, Lin M, Rockowitz S, et al.: Characterization of Human Pseudogene-
Derived Non-Coding RNAs for Functional Potential. PLoS One. 2014; 9(4): 
e93972.  
PubMed Abstract | Publisher Full Text | Free Full Text 
16. McGowan SJ, Terrett J, Brown CG, et al.: Annotation of the human genome 
by high-throughput sequence analysis of naturally occurring proteins. Curr 
Proteomics. 2004; 1(1): 41–48.  
Publisher Full Text 
17. Desiere F, Deutsch EW, King NL, et al.: The PeptideAtlas project. Nucleic Acids 
Res. 2006; 34(Database issue): D655–8.  
PubMed Abstract | Publisher Full Text | Free Full Text 
18. Omenn GS, Lane L, Lundberg EK, et al.: Metrics for the Human Proteome Project 
2016: Progress on Identifying and Characterizing the Human Proteome, Including 
Post-Translational Modifications. J Proteome Res. 2016; 15(11): 3951–3960.  
PubMed Abstract | Publisher Full Text | Free Full Text 
19. Segura V, Garin-Muga A, Guruceaga E, et al.: Progress and pitfalls in finding the 
‘missing proteins’ from the human proteome map. Expert Rev Proteomics. 2017; 
14(1): 9–14.  
PubMed Abstract | Publisher Full Text 
20. Fagerberg L, Hallström BM, Oksvold P, et al.: Analysis of the human tissue-
specific expression by genome-wide integration of transcriptomics and 
antibody-based proteomics. Mol Cell Proteomics. 2014; 13(2): 397–406.  
PubMed Abstract | Publisher Full Text | Free Full Text 
21. Uhlen M, Bandrowski A, Carr S, et al.: A proposal for validation of antibodies. 
Nat Methods. 2016; 13(10): 823–7.  
PubMed Abstract | Publisher Full Text 
22. Pueyo JI, Magny EG, Couso JP: New Peptides Under the s(ORF)ace of the 
Genome. Trends Biochem Sci. 2016; 41(8): 665–678.  
PubMed Abstract | Publisher Full Text 
23. Schmitz JF, Bornberg-Bauer E: Fact or fiction: updates on how protein-coding 
genes might emerge de novo from previously non-coding DNA [version 1; 
referees: 3 approved]. F1000Res. 2017; 6(F1000 Faculty Rev): 57.  
PubMed Abstract | Publisher Full Text | Free Full Text 
24. Mumtaz MA, Couso JP: Ribosomal profiling adds new coding sequences to the 
proteome. Biochem Soc Trans. 2015; 43(6): 1271–1276.  
PubMed Abstract | Publisher Full Text 
25. Nelson BR, Makarewich CA, Anderson DM, et al.: A peptide encoded by a 
transcript annotated as long noncoding RNA enhances SERCA activity in 
muscle. Science. 2016; 351(6270): 271–5.  
PubMed Abstract | Publisher Full Text | Free Full Text 
26. Yang P, Read C, Kuc RE, et al.: Elabela/Toddler Is an Endogenous Agonist of 
the Apelin APJ Receptor in the Adult Cardiovascular System, and Exogenous 
Administration of the Peptide Compensates for the Downregulation of its 
Expression in Pulmonary Arterial Hypertension. Circulation. 2017; 135(12): 
1160–1173.  
PubMed Abstract | Publisher Full Text | Free Full Text 
27. Hon CC, Ramilowski JA, Harshbarger J, et al.: An atlas of human long non-
coding RNAs with accurate 5′ ends. Nature. 2017; 543(7644): 199–204.  
PubMed Abstract | Publisher Full Text 
28. Southan C, Sharman JL, Benson HE, et al.: The IUPHAR/BPS Guide to 
PHARMACOLOGY in 2016: towards curated quantitative interactions between 
1300 protein targets and 6000 ligands. Nucleic Acids Res. 2016; 44(D1): D1054–68. 
PubMed Abstract | Publisher Full Text | Free Full Text 
29. Mudge JM, Harrow J: The state of play in higher eukaryote gene annotation.  
Nat Rev Genet. 2016; 17(12): 758–772.  
PubMed Abstract | Publisher Full Text 
30. Narasimhan VM, Hunt KA, Mason D, et al.: Health and population effects of 
rare gene knockouts in adult humans with related parents. Science. 2016; 
352(6284): 474–477.  
PubMed Abstract | Publisher Full Text | Free Full Text 
31. Griss J, Martín M, O’Donovan C, et al.: Consequences of the discontinuation 
of the International Protein Index (IPI) database and its substitution by the 
UniProtKB “complete proteome” sets. Proteomics. 2011; 11(22): 4434–4438.  
PubMed Abstract | Publisher Full Text | Free Full Text 
32. Perez-Riverol Y, Vizcaíno JA: Synthetic human proteomes for accelerating 
protein research. Nat Methods. 2017; 14(3): 240–242.  
PubMed Abstract | Publisher Full Text 
33. Southan C: Supplementary data for assessing the human canonical protein 
count. figshare. 2017.  
Data Source 
Page 12 of 22
F1000Research 2017, 6:448 Last updated: 18 MAY 2017
 Open Peer Review
   Current Referee Status:
Version 1
 09 May 2017Referee Report
doi:10.5256/f1000research.11995.r22248
































Page 13 of 22
















Is the topic of the review discussed comprehensively in the context of the current literature?
Yes
Are all factual statements correct and adequately supported by citations?
Partly
Is the review written in accessible language?
Yes
Are the conclusions drawn appropriate in the context of the current research literature?
Partly
 We are working for UniProtKB/Swiss-ProtCompeting Interests:
We have read this submission. We believe that we have an appropriate level of expertise to
confirm that it is of an acceptable scientific standard, however we have significant reservations,
as outlined above.





Page 14 of 22










































Page 15 of 22









































Page 16 of 22










































Page 17 of 22













Coding Loci. . 2015;   (12): 4945-8   |   J Proteome Res 14 PubMed Abstract Publisher Full Text
Is the topic of the review discussed comprehensively in the context of the current literature?
Yes
Are all factual statements correct and adequately supported by citations?
Partly
Is the review written in accessible language?
Yes
Are the conclusions drawn appropriate in the context of the current research literature?
Partly
 I am the Project Coordinator and one of the PIs of the HGNC projectCompeting Interests:
I have read this submission. I believe that I have an appropriate level of expertise to confirm that






Page 18 of 22






































Page 19 of 22





































Page 20 of 22




































Page 21 of 22







expressed protein-coding genes have a single dominant isoform. . 2015;   (4): 1880-7 J Proteome Res 14
 |   PubMed Abstract Publisher Full Text
Is the topic of the review discussed comprehensively in the context of the current literature?
Yes
Are all factual statements correct and adequately supported by citations?
Partly
Is the review written in accessible language?
Yes
Are the conclusions drawn appropriate in the context of the current research literature?
Yes
 I am part of the GENCODE ConsortiumCompeting Interests:
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
Page 22 of 22
F1000Research 2017, 6:448 Last updated: 18 MAY 2017
